Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

74 publications

Funding

4 grants

Active

2 grants
  • PI
    Moderate to Severe COVID-19 Breakthrough Infections After COVID-19 Vaccination and Predictors in Immunocompromised Renal Transplant Recipients
    Merck Sharp & Dohme LLC · 2023–2026Contract
    SRA 231358-01
  • Co-I
    ARLG Pneumonia Direct Pilot ("Study")
    National Institute of Allergy and Infectious Diseases · 2023–2026 · via Duke University
    UM1AI104681-11
Completed grants (2)
  • Sub-PI
    A randomized study to evaluate antibody response to an additional dose of SARS-CoV-2 vaccination with and without immunosuppression reduction in kidney and liver transplant recipients
    National Institute of Allergy and Infectious Diseases · 2020–2025 · via The Johns Hopkins University· 2 renewals
    U01AI138897-05S2
  • Sub-PI
    HOPE in Action
    National Institute of Allergy and Infectious Diseases · 2018–2023 · via The Johns Hopkins University
    U01AI134591-05

Clinical research

15 studies

Active

4 studies
  • PI
    A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)
    PHASE2 · GlaxoSmithKline · OPEN TO ACCRUAL (as of 2025)
    Respiratory Syncytial Virus Infections
    NCT07092865
  • PI
    Liver Transplantation from Donors with HIV for Recipients with HIV: Long Term Follow up Study
    The Johns Hopkins University · OPEN TO ACCRUAL (as of 2025)
  • PI
    A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression
    PHASE3 · Merck Sharp & Dohme LLC · OPEN TO ACCRUAL (as of 2025)
    Coronavirus Disease (COVID-19)
    NCT06667700
  • PI
    HOPE in Action Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes
    NA · The Johns Hopkins University · OPEN TO ACCRUAL (as of 2021)
    Hiv
    NCT06263426
Completed & closed trials (11)
  • PI
    A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age) Receiving 1 Dose.
    PHASE2 · GSK Research & Development Limited · IRB STUDY CLOSURE (as of 2025)
    Respiratory Syncytial Virus Infections
    NCT05921903
  • PI
    A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
    PHASE2 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2025)
    RSV Infection
    NCT06585150
  • PI
    A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
    PHASE2 · The Johns Hopkins University · IRB STUDY CLOSURE (as of 2025)
    Kidney Transplant Recipients; Liver Transplant Recipients
    NCT05077254
  • PI
    HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
    NA · National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2024)
    Hiv
    NCT03734393
  • PI
    The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed Human Immunodeficiency Viruses (HIV)-Positive Patients Post-Renal Transplant
    PHASE4 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
    HIV Infections; Renal Transplant Rejection
    NCT04530630
  • PI
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19
    PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2022)
    COVID-19
    NCT04745351
  • PI
    Retrospective Study to Collect Follow-Up Data at 12 Months Among Transplant Recipients with Refractory or Resistant Cytomegalovirus Infections Randomized to the Maribavir Treatment Arm in the SHP620-303 Open-label Phase III Trial
    Takeda Pharmaceutical Company Limited · IRB STUDY CLOSURE (as of 2022)
  • PI
    A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
    PHASE2 · Janssen Research & Development, LLC · IRB STUDY CLOSURE (as of 2022)
    Respiratory Syncytial Virus Infections
    NCT04056611
  • PI
    Multinational CMV Outcomes, Treatment Patterns and Healthcare Resource Utilization Studies (OTUS) following Solid Organ Transplant
    Takeda Pharmaceutical Company Limited · IRB STUDY CLOSURE (as of 2022)
  • PI
    Multinational CMV Outcomes, Treatment Patterns and Healthcare Resource Utilization Studies (OTUS) following Hematopoietic Stem Cell Transplant (HSCT)
    Takeda Pharmaceutical Company Limited · IRB STUDY CLOSURE (as of 2022)
  • PI
    A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
    PHASE2 · Karyopharm Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2021)
    Coronavirus Infection
    NCT04349098